| Year |
Citation |
Score |
| 2024 |
McDaniel JM, Morrissey RL, Dibra D, Patel LR, Xiong S, Zhang Y, Chau GP, Su X, Qi Y, El-Naggar AK, Lozano G. p53R172H and p53R245W Hotspot Mutations Drive Distinct Transcriptomes in Mouse Mammary Tumors Through a Convergent Transcriptional Mediator. Cancer Research Communications. PMID 38994678 DOI: 10.1158/2767-9764.CRC-24-0128 |
0.412 |
|
| 2024 |
Dibra D, Xiong S, Moyer SM, El-Naggar AK, Qi Y, Su X, Kong EK, Korkut A, Lozano G. Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo. Science Advances. 10: eadk1835. PMID 38354236 DOI: 10.1126/sciadv.adk1835 |
0.511 |
|
| 2024 |
Dibra D, Gagea M, Qi Y, Chau GP, Su X, Lozano G. p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis. Cancer Research Communications. 3: 2640-2652. PMID 38047594 DOI: 10.1158/2767-9764.CRC-23-0218 |
0.307 |
|
| 2023 |
Dibra D, Moyer SM, El-Naggar AK, Qi Y, Su X, Lozano G. Triple-negative breast tumors are dependent on mutant p53 for growth and survival. Proceedings of the National Academy of Sciences of the United States of America. 120: e2308807120. PMID 37579145 DOI: 10.1073/pnas.2308807120 |
0.471 |
|
| 2023 |
Chachad D, Patel LR, Recio CV, Pourebrahim R, Whitley EM, Wang W, Su X, Xu A, Lee DF, Lozano G. Unique transcriptional profiles underlie osteosarcomagenesis driven by different p53 mutants. Cancer Research. PMID 37205631 DOI: 10.1158/0008-5472.CAN-22-3464 |
0.529 |
|
| 2023 |
Gencel-Augusto J, Su X, Qi Y, Whitley EM, Pant V, Xiong S, Shah V, Lin J, Perez E, Fiorotto ML, Mahmud I, Jain AK, Lorenzi PL, Navin NE, Richie ER, ... Lozano G, et al. Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program. Cancer Discovery. OF1-OF20. PMID 37067911 DOI: 10.1158/2159-8290.CD-22-0872 |
0.561 |
|
| 2023 |
Pant V, Sun C, Lozano G. Tissue specificity and spatio-temporal dynamics of the p53 transcriptional program. Cell Death and Differentiation. PMID 36755072 DOI: 10.1038/s41418-023-01123-2 |
0.441 |
|
| 2022 |
Sun C, Estrella JS, Whitley EM, Chau GP, Lozano G, Wasylishen AR. Mouse modeling provides insights into Daxx and Atrx tumor suppressive mechanisms in the endocrine pancreas. Disease Models & Mechanisms. PMID 35976056 DOI: 10.1242/dmm.049552 |
0.335 |
|
| 2022 |
Barton MC, Lozano G. p53 Activation Paradoxically Causes Liver Cancer. Cancer Research. 82: 2824-2825. PMID 35971677 DOI: 10.1158/0008-5472.CAN-22-2065 |
0.457 |
|
| 2022 |
Ding J, Li X, Khan S, Zhang C, Gao F, Sen S, Wasylishen AR, Zhao Y, Lozano G, Koul D, Yung WKA. EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a non-canonical regulatory axis between EGFR and wild-type p53 in glioblastoma. Neuro-Oncology. PMID 35474131 DOI: 10.1093/neuonc/noac105 |
0.392 |
|
| 2022 |
Xiong S, Chachad D, Zhang Y, Gencel-Augusto J, Sirito M, Pant V, Yang P, Sun C, Chau G, Qi Y, Su X, Whitley EM, El-Naggar AK, Lozano G. Differential gain-of-function activity of three p53 hotspot mutants in vivo. Cancer Research. PMID 35320355 DOI: 10.1158/0008-5472.CAN-21-3376 |
0.432 |
|
| 2022 |
Pant V, Aryal NK, Xiong S, Chau GP, Fowlkes NW, Lozano G. Alterations of the MDM2 C-terminus differentially impact its function in vivo. Cancer Research. PMID 35078816 DOI: 10.1158/0008-5472.CAN-21-2381 |
0.418 |
|
| 2021 |
Zhou X, Beilter A, Xu Z, Gao R, Xiong S, Paulucci-Holthauzen A, Lozano G, de Crombrugghe B, Gorlick R. Wnt/ß-catenin-mediated p53 suppression is indispensable for osteogenesis of mesenchymal progenitor cells. Cell Death & Disease. 12: 521. PMID 34021120 DOI: 10.1038/s41419-021-03758-w |
0.418 |
|
| 2021 |
Kim MP, Li X, Deng J, Zhang Y, Dai B, Allton KL, Hughes TG, Siangco C, Augustine JJ, Kang Y, McDaniel JM, Xiong S, Koay EJ, McAllister F, Bristow CA, ... ... Lozano G, et al. Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. Cancer Discovery. PMID 33839689 DOI: 10.1158/2159-8290.CD-20-1228 |
0.433 |
|
| 2021 |
Jeffers JR, Pinto EM, Rehg JE, Clay MR, Wang J, Neale G, Heath RJ, Lozano G, Lalli E, Figueiredo BC, Pappo AS, Rodriguez-Galindo C, Chen W, Pounds S, Ribeiro RC, et al. The Common Germline TP53-R337H Mutation is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. Cancer Research. PMID 33637564 DOI: 10.1158/0008-5472.CAN-20-1750 |
0.42 |
|
| 2020 |
Moyer SM, Wasylishen AR, Qi Y, Fowlkes N, Su X, Lozano G. p53 drives a transcriptional program that elicits a non-cell-autonomous response and alters cell state in vivo. Proceedings of the National Academy of Sciences of the United States of America. PMID 32900967 DOI: 10.1073/Pnas.2008474117 |
0.562 |
|
| 2020 |
Gencel-Augusto J, Lozano G. p53 tetramerization: at the center of the dominant-negative effect of mutant p53. Genes & Development. 34: 1128-1146. PMID 32873579 DOI: 10.1101/Gad.340976.120 |
0.621 |
|
| 2020 |
Wasylishen AR, Sun C, Moyer SM, Qi Y, Chau GP, Aryal NK, McAllister F, Kim MP, Barton MC, Estrella JS, Su X, Lozano G. Daxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo. Science Advances. 6: eaba8415. PMID 32821827 DOI: 10.1126/Sciadv.Aba8415 |
0.41 |
|
| 2020 |
Wasylishen AR, Sun C, Chau GP, Qi Y, Su X, Kim MP, Estrella JS, Lozano G. Men1 maintains exocrine pancreas homeostasis in response to inflammation and oncogenic stress. Proceedings of the National Academy of Sciences of the United States of America. PMID 32156729 DOI: 10.1073/Pnas.1920017117 |
0.305 |
|
| 2019 |
Haupt S, Caramia F, Herschtal A, Soussi T, Lozano G, Chen H, Liang H, Speed TP, Haupt Y. Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. Nature Communications. 10: 5385. PMID 31772231 DOI: 10.1038/S41467-019-13266-3 |
0.465 |
|
| 2019 |
Pant V, Xiong S, Wasylishen AR, Larsson CA, Aryal NK, Chau G, Tailor RC, Lozano G. Transient enhancement of p53 activity protects from radiation-induced gastrointestinal toxicity. Proceedings of the National Academy of Sciences of the United States of America. PMID 31409715 DOI: 10.1073/Pnas.1909550116 |
0.588 |
|
| 2019 |
Lozano G. Restoring p53 in cancer: the promises and the challenges. Journal of Molecular Cell Biology. PMID 31283825 DOI: 10.1093/Jmcb/Mjz063 |
0.459 |
|
| 2019 |
Aryal NK, Pant V, Wasylishen AR, Rimel B, Baseler L, El-Naggar AK, Mutch DG, Goodfellow PJ, Arur S, Lozano G. Dicer1 phospho-mimetic promotes tumor progression and dissemination. Cancer Research. PMID 30914430 DOI: 10.1158/0008-5472.Can-18-2460 |
0.442 |
|
| 2019 |
Ding J, Li X, Zhang C, Gao F, Wu S, Wasylishen A, Baggerly K, Lozano G, Koul D, Yung A. CBMT-32. EGFR SUPPRESSES p53 FUNCTION THROUGH DNA-PKcs BINDING TO p53: NOVEL CROSSTALK BETWEEN EGFR AND TP53 IN GLIOBLASTOMA Neuro-Oncology. 21: vi40-vi40. DOI: 10.1093/Neuonc/Noz175.154 |
0.394 |
|
| 2018 |
Kim MP, Lozano G. Mutant p53 partners in crime. Cell Death and Differentiation. 25: 161-168. PMID 31745305 DOI: 10.1038/cdd.2017.185 |
0.419 |
|
| 2018 |
Aryal NK, Pant V, Wasylishen AR, Parker-Thornburg J, Baseler L, El-Naggar AK, Liu B, Kalia A, Lozano G, Arur S. Constitutive Dicer1 phosphorylation accelerates metabolism and aging in vivo. Proceedings of the National Academy of Sciences of the United States of America. PMID 30593561 DOI: 10.1073/Pnas.1814377116 |
0.33 |
|
| 2018 |
Aryal NK, Wasylishen AR, Lozano G. CRISPR/Cas9 can mediate high-efficiency off-target mutations in mice in vivo. Cell Death & Disease. 9: 1099. PMID 30368519 DOI: 10.1038/S41419-018-1146-0 |
0.355 |
|
| 2018 |
Zhang Y, Xiong S, Liu B, Pant V, Celii F, Chau G, Elizondo-Fraire AC, Yang P, You MJ, El-Naggar AK, Navin NE, Lozano G. Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases. Nature Communications. 9: 3953. PMID 30262850 DOI: 10.1038/S41467-018-06146-9 |
0.354 |
|
| 2018 |
Wasylishen AR, Estrella JS, Pant V, Chau GP, Lozano G. Daxx Functions are p53-independent In Vivo. Molecular Cancer Research : McR. PMID 29903771 DOI: 10.1158/1541-7786.Mcr-18-0281 |
0.567 |
|
| 2018 |
Ortiz GJ, Lozano G. SNPing away at mutant p53 activities. Genes & Development. 32: 195-196. PMID 29491132 DOI: 10.1101/Gad.312934.118 |
0.542 |
|
| 2018 |
Larsson CA, Moyer SM, Liu B, Michel KA, Pant V, Yang P, Wong J, El-Naggar AK, Krahe R, Lozano G. Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration. Proceedings of the National Academy of Sciences of the United States of America. PMID 29440484 DOI: 10.1073/Pnas.1719001115 |
0.607 |
|
| 2018 |
Zhang Y, Xiong S, Lozano G. Abstract IA08: Somatic p53 mutations drive development of triple-negative breast cancer with evolutionarily distinct metastases Cancer Research. 78. DOI: 10.1158/1538-7445.Mousemodels17-Ia08 |
0.448 |
|
| 2017 |
Zhang Y, Lozano G. p53: Multiple Facets of a Rubik's Cube. Annual Review of Cancer Biology. 1: 185-201. PMID 30775651 DOI: 10.1146/annurev-cancerbio-050216-121926 |
0.517 |
|
| 2017 |
Aryal NK, Wasylishen AR, Pant V, Riley-Croce M, Lozano G. Loss of digestive organ expansion factor (Diexf) reveals an essential role during murine embryonic development that is independent of p53. Oncotarget. 8: 103996-104006. PMID 29262616 DOI: 10.18632/Oncotarget.22087 |
0.617 |
|
| 2017 |
Liu B, Mitani Y, Rao X, Zafereo M, Zhang J, Zhang J, Futreal PA, Lozano G, El-Naggar AK. Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma. Journal of the National Cancer Institute. 109. PMID 29117356 DOI: 10.1093/Jnci/Djx033 |
0.323 |
|
| 2017 |
Kim MP, Lozano G. Mutant p53 partners in crime. Cell Death and Differentiation. PMID 29099488 DOI: 10.1038/Cdd.2017.185 |
0.517 |
|
| 2017 |
Pourebrahim R, Zhang Y, Liu B, Gao R, Xiong S, Lin PP, McArthur MJ, Ostrowski MC, Lozano G. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein. Genes & Development. PMID 29021240 DOI: 10.1101/Gad.304972.117 |
0.614 |
|
| 2017 |
Ortiz GJ, Li Y, Post SM, Pant V, Xiong S, Larsson CA, El-Naggar AK, Johnson DG, Lozano G. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes. Oncogene. PMID 28925402 DOI: 10.1038/Onc.2017.344 |
0.552 |
|
| 2017 |
Pant V, Larsson CA, Aryal N, Xiong S, You MJ, Quintas-Cardama A, Lozano G. Tumorigenesis promotes Mdm4-S overexpression. Oncotarget. 8: 25837-25847. PMID 28460439 DOI: 10.18632/Oncotarget.15552 |
0.517 |
|
| 2017 |
Moyer SM, Larsson CA, Lozano G. Mdm proteins: critical regulators of embry ogenesis and homeostasis. Journal of Molecular Cell Biology. PMID 28093454 DOI: 10.1093/Jmcb/Mjx004 |
0.551 |
|
| 2017 |
Pourebrahimabadi R, Zhang Y, McArthur MJ, Lozano G. Abstract 3030: Mutant p53-driven metastasis explored utilizing a traceable, conditional osteosarcoma model Cancer Research. 77: 3030-3030. DOI: 10.1158/1538-7445.Am2017-3030 |
0.478 |
|
| 2017 |
Ding J, Li X, Wasylishen A, Gao F, Zhao Y, Baggerly K, Lozano G, Koul D, Yung WKA. CBIO-02. AMPLIFIED EGFR DRIVES TUMORIGENESIS IN TP53 WILD TYPE GLIOBLASTOMA THROUGH INHIBITION OF p53 FUNCTION BY DNA-PK/p53 BINDING Neuro-Oncology. 19: vi33-vi33. DOI: 10.1093/Neuonc/Nox168.125 |
0.504 |
|
| 2016 |
Lozano G. The Enigma of p53. Cold Spring Harbor Symposia On Quantitative Biology. PMID 27932563 DOI: 10.1101/Sqb.2016.81.031062 |
0.583 |
|
| 2016 |
Xiong S, Pant V, Zhang Y, Aryal NK, James You M, Kusewitt D, Lozano G. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumorigenesis. The Journal of Pathology. PMID 27925213 DOI: 10.1002/Path.4854 |
0.577 |
|
| 2016 |
Tonnessen-Murray CA, Lozano G, Jackson JG. The Regulation of Cellular Functions by the p53 Protein: Cellular Senescence. Cold Spring Harbor Perspectives in Medicine. PMID 27881444 DOI: 10.1101/Cshperspect.A026112 |
0.585 |
|
| 2016 |
Wasylishen AR, Lozano G. Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. Cold Spring Harbor Perspectives in Medicine. PMID 27329033 DOI: 10.1101/Cshperspect.A026211 |
0.484 |
|
| 2016 |
Pant V, Xiong S, Chau G, Tsai K, Shetty G, Lozano G. Distinct downstream targets manifest p53-dependent pathologies in mice. Oncogene. PMID 27065327 DOI: 10.1038/Onc.2016.111 |
0.641 |
|
| 2016 |
Dibra D, Mitra A, Newman M, Xia X, Cutrera JJ, Gagea M, Kleinerman ES, Lozano G, Li S. Lack of immunomodulatory Interleukin-27 enhances oncogenic properties of mutant p53 in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26979394 DOI: 10.1158/1078-0432.Ccr-15-2052 |
0.555 |
|
| 2016 |
Xie X, Lozano G, Siddik ZH. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene. PMID 26876197 DOI: 10.1038/onc.2016.12 |
0.538 |
|
| 2016 |
Lozano G. Abstract IA21: Mutant p53 activities in tumor development. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-Ia21 |
0.644 |
|
| 2016 |
Xiong S, Zhang Y, Lozano G. Abstract B07: Gain of function activities of p53R245W in a conditional knock-in mouse model Cancer Research. 76. DOI: 10.1158/1538-7445.Tummet15-B07 |
0.586 |
|
| 2016 |
Zhang Y, Xiong S, Pant V, El-Naggar A, Lozano G. Abstract P3-03-03: A mouse model of sporadic breast tumor with a conditionalP53mutation Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-03-03 |
0.65 |
|
| 2016 |
Lozano G. Abstract SY04-01: The in vivo gain-of-function activities of mutant p53 Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Sy04-01 |
0.607 |
|
| 2015 |
Wienken M, Dickmanns A, Nemajerova A, Kramer D, Najafova Z, Weiss M, Karpiuk O, Kassem M, Zhang Y, Lozano G, Johnsen SA, Moll UM, Zhang X, Dobbelstein M. MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53. Molecular Cell. PMID 26748827 DOI: 10.1016/J.Molcel.2015.12.008 |
0.509 |
|
| 2015 |
Dibra D, Xia X, Mitra A, Cutrera JJ, Lozano G, Li S. Mutant p53 in concert with an IL27 Receptor α deficiency causes spontaneous liver inflammation, fibrosis, and steatosis. Hepatology (Baltimore, Md.). PMID 26637970 DOI: 10.1002/Hep.28379 |
0.441 |
|
| 2015 |
Mitani Y, Liu B, Rao P, Borra V, Zafereo M, Weber RS, Kies MS, Lozano G, Futreal A, Caulin C, El-Naggar A. Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26631609 DOI: 10.1158/1078-0432.Ccr-15-2867-T |
0.316 |
|
| 2015 |
Kim MP, Zhang Y, Lozano G. Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer. Frontiers in Oncology. 5: 249. PMID 26618142 DOI: 10.3389/Fonc.2015.00249 |
0.614 |
|
| 2015 |
Tashakori M, Zhang Y, Xiong S, You MJ, Lozano G. p53 Activity Dominates that of p73 upon Mdm4 Loss in Development and Tumorigenesis. Molecular Cancer Research : McR. PMID 26527653 DOI: 10.1158/1541-7786.MCR-15-0346 |
0.588 |
|
| 2015 |
Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM. Corrigendum: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature. PMID 26416737 DOI: 10.1038/Nature15720 |
0.403 |
|
| 2015 |
Charni M, Molchadsky A, Goldstein I, Solomon H, Tal P, Goldfinger N, Yang P, Porat Z, Lozano G, Rotter V. Novel p53 target genes secreted by the liver are involved in non-cell-autonomous regulation. Cell Death and Differentiation. PMID 26358154 DOI: 10.1038/Cdd.2015.119 |
0.57 |
|
| 2015 |
Goh AM, Xue Y, Leushacke M, Li L, Wong JS, Chiam PC, Rahmat SA, Mann MB, Mann KM, Barker N, Lozano G, Terzian T, Lane DP. Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice. Oncotarget. 6: 17968-80. PMID 26255629 DOI: 10.18632/Oncotarget.4956 |
0.61 |
|
| 2015 |
Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature. 523: 352-6. PMID 26009011 DOI: 10.1038/Nature14430 |
0.454 |
|
| 2015 |
Mancini F, Pieroni L, Monteleone V, Lucà R, Fici L, Luca E, Urbani A, Xiong S, Soddu S, Masetti R, Lozano G, Pontecorvi A, Moretti F. MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response. Oncogene. PMID 25961923 DOI: 10.1038/onc.2015.76 |
0.512 |
|
| 2015 |
Riley MF, You MJ, Multani AS, Lozano G. Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma. Oncogene. PMID 25915849 DOI: 10.1038/Onc.2015.88 |
0.633 |
|
| 2015 |
Vilimas T, Collins K, Guerin T, Awasthi R, Feigenbaum L, Lozano G, Dyke TV, Kozlov S. Abstract A17: p53 missense mutants R172H and R270H exhibit differential effects on tumorigenesis Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A17 |
0.621 |
|
| 2014 |
Pant V, Lozano G. Limiting the power of p53 through the ubiquitin proteasome pathway. Genes & Development. 28: 1739-51. PMID 25128494 DOI: 10.1101/Gad.247452.114 |
0.613 |
|
| 2014 |
Xiong S, Tu H, Kollareddy M, Pant V, Li Q, Zhang Y, Jackson JG, Suh YA, Elizondo-Fraire AC, Yang P, Chau G, Tashakori M, Wasylishen AR, Ju Z, Solomon H, ... ... Lozano G, et al. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proceedings of the National Academy of Sciences of the United States of America. 111: 11145-50. PMID 25024203 DOI: 10.1073/Pnas.1404139111 |
0.647 |
|
| 2014 |
Quintás-Cardama A, Post SM, Solis LM, Xiong S, Yang P, Chen N, Wistuba II, Killary AM, Lozano G. Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. The Journal of Pathology. 234: 108-19. PMID 24890125 DOI: 10.1002/Path.4385 |
0.318 |
|
| 2014 |
Yokoyama M, Okada S, Nakagomi A, Moriya J, Shimizu I, Nojima A, Yoshida Y, Ichimiya H, Kamimura N, Kobayashi Y, Ohta S, Fruttiger M, Lozano G, Minamino T. Inhibition of endothelial p53 improves metabolic abnormalities related to dietary obesity. Cell Reports. 7: 1691-703. PMID 24857662 DOI: 10.1016/J.Celrep.2014.04.046 |
0.458 |
|
| 2014 |
Zhang Y, Xiong S, Li Q, Hu S, Tashakori M, Van Pelt C, You MJ, Pageon L, Lozano G. Tissue-specific and age-dependent effects of global Mdm2 loss. The Journal of Pathology. 233: 380-91. PMID 24789767 DOI: 10.1002/Path.4368 |
0.509 |
|
| 2014 |
Zou Q, Jin J, Hu H, Li HS, Romano S, Xiao Y, Nakaya M, Zhou X, Cheng X, Yang P, Lozano G, Zhu C, Watowich SS, Ullrich SE, Sun SC. USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nature Immunology. 15: 562-70. PMID 24777531 DOI: 10.1038/Ni.2885 |
0.384 |
|
| 2014 |
Pant V, Lozano G. Dissecting the p53-Mdm2 feedback loop in vivo: uncoupling the role in p53 stability and activity. Oncotarget. 5: 1149-56. PMID 24658419 DOI: 10.18632/Oncotarget.1797 |
0.596 |
|
| 2014 |
Li Q, Zhang Y, El-Naggar AK, Xiong S, Yang P, Jackson JG, Chau G, Lozano G. Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Molecular Cancer Research : McR. 12: 901-11. PMID 24598047 DOI: 10.1158/1541-7786.Mcr-14-0089 |
0.64 |
|
| 2014 |
Eischen CM, Lozano G. The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Human Mutation. 35: 728-37. PMID 24488925 DOI: 10.1002/Humu.22524 |
0.55 |
|
| 2014 |
Lozano G. Abstract SY07-03: Gain-of-function activities of mutant p53 Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Sy07-03 |
0.614 |
|
| 2014 |
Wasylishen AR, Lozano G. Abstract 3917: Understanding the mechanisms driving pancreatic neuroendocrine tumorigenesis Cancer Research. 74: 3917-3917. DOI: 10.1158/1538-7445.Am2014-3917 |
0.494 |
|
| 2013 |
Tordella L, Koch S, Salter V, Pagotto A, Doondeea JB, Feller SM, Ratnayaka I, Zhong S, Goldin RD, Lozano G, McKeon FD, Tavassoli M, Fritzsche F, Huber GF, Rössle M, et al. ASPP2 suppresses squamous cell carcinoma via RelA/p65-mediated repression of p63. Proceedings of the National Academy of Sciences of the United States of America. 110: 17969-74. PMID 24127607 DOI: 10.1073/Pnas.1309362110 |
0.621 |
|
| 2013 |
Pant V, Xiong S, Jackson JG, Post SM, Abbas HA, Quintás-Cardama A, Hamir AN, Lozano G. The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes & Development. 27: 1857-67. PMID 23973961 DOI: 10.1101/Gad.227249.113 |
0.613 |
|
| 2013 |
Chen N, Balasenthil S, Reuther J, Frayna A, Wang Y, Chandler DS, Abruzzo LV, Rashid A, Rodriguez J, Lozano G, Cao Y, Lokken E, Chen J, Frazier ML, Sahin AA, et al. DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-β-driven epithelial-mesenchymal transition. Cancer Discovery. 3: 1172-89. PMID 23838884 DOI: 10.1158/2159-8290.Cd-12-0499 |
0.717 |
|
| 2013 |
Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, Rozenfeld N, Harpaz N, Itzkowitz S, Harris CC, Rotter V, et al. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 23: 634-46. PMID 23680148 DOI: 10.1016/J.Ccr.2013.03.022 |
0.496 |
|
| 2013 |
Haupt S, Mitchell C, Corneille V, Shortt J, Fox S, Pandolfi PP, Castillo-Martin M, Bonal DM, Cordon-Cardo C, Lozano G, Haupt Y. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle (Georgetown, Tex.). 12: 1722-31. PMID 23656786 DOI: 10.4161/Cc.24805 |
0.618 |
|
| 2013 |
Chen YC, Chan JY, Chiu YL, Liu ST, Lozano G, Wang SL, Ho CL, Huang SM. Grail as a molecular determinant for the functions of the tumor suppressor p53 in tumorigenesis. Cell Death and Differentiation. 20: 732-43. PMID 23370271 DOI: 10.1038/Cdd.2013.1 |
0.619 |
|
| 2013 |
Jackson JG, Lozano G. The mutant p53 mouse as a pre-clinical model. Oncogene. 32: 4325-30. PMID 23318424 DOI: 10.1038/Onc.2012.610 |
0.624 |
|
| 2013 |
Li Q, Lozano G. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 34-41. PMID 23262034 DOI: 10.1158/1078-0432.Ccr-12-0053 |
0.607 |
|
| 2013 |
Larsson CA, Kojima K, Wang Y, Navin N, Gallardo M, Primo D, Rojas JL, Martinez J, Manshouri T, Lee HJ, Bradner JE, Ballesteros J, Post SM, Lozano G(, Quintás-Cardama A. BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The Eμ-TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent Of TP53 Mutation Status Blood. 122: 876-876. DOI: 10.1182/Blood.V122.21.876.876 |
0.527 |
|
| 2013 |
Lozano G. Abstract CN02-01: Factors that impinge on the p53 pathway modify cancer risk Cancer Prevention Research. 6. DOI: 10.1158/1940-6215.Prev-13-Cn02-01 |
0.482 |
|
| 2012 |
Riley MF, Lozano G. The Many Faces of MDM2 Binding Partners. Genes & Cancer. 3: 226-39. PMID 23150756 DOI: 10.1177/1947601912455322 |
0.552 |
|
| 2012 |
Pant V, Quintás-Cardama A, Lozano G. The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood. 120: 5118-27. PMID 23018641 DOI: 10.1182/Blood-2012-05-356014 |
0.618 |
|
| 2012 |
Flores ER, Lozano G. The p53 family grows old. Genes & Development. 26: 1997-2000. PMID 22987633 DOI: 10.1101/Gad.202648.112 |
0.579 |
|
| 2012 |
Jackson JG, Lozano G. Che-ating death: CHE1/AATF protects from p53-mediated apoptosis. The Embo Journal. 31: 3951-3. PMID 22960635 DOI: 10.1038/Emboj.2012.258 |
0.399 |
|
| 2012 |
Jackson JG, Pant V, Li Q, Chang LL, Quintás-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, El-Naggar AK, Lozano G. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell. 21: 793-806. PMID 22698404 DOI: 10.1016/J.Ccr.2012.04.027 |
0.604 |
|
| 2012 |
Xiong S, Parker-Thornburg J, Lozano G. Developing genetically engineered mouse models to study tumor suppression. Current Protocols in Mouse Biology. 2: 9-24. PMID 22582146 DOI: 10.1002/9780470942390.Mo110159 |
0.47 |
|
| 2012 |
Hallenborg P, Feddersen S, Francoz S, Murano I, Sundekilde U, Petersen RK, Akimov V, Olson MV, Lozano G, Cinti S, Gjertsen BT, Madsen L, Marine JC, Blagoev B, Kristiansen K. Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. Cell Death and Differentiation. 19: 1381-9. PMID 22388350 DOI: 10.1038/Cdd.2012.15 |
0.49 |
|
| 2012 |
Quintas-Cardama A, Post SM, Solis L, Xiong S, Wistuba II, Lozano G. DEAR1, a novel tumor suppressor, negative regulator of epithelial-mesenchymal transition, and prognostic factor in non-small cell lung cancer. Journal of Clinical Oncology. 30: 10506-10506. DOI: 10.1200/Jco.2012.30.15_Suppl.10506 |
0.462 |
|
| 2012 |
Lozano G, Jackson JG. Abstract SY14-02: p53-mediated senescence impairs the apoptotic response to chemotherapy in breast cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy14-02 |
0.363 |
|
| 2012 |
Lin S, Yu L, Yang J, Liu Z, Karia B, Bishop AJR, Jackson J, Lozano G, Copland JA, Mu X, Sun B, Sun L. Abstract 1069: Mutant p53 disrupts the role of ShcA in balancing the Smad-dependent and -independent signaling activity of TGF-β Cancer Research. 72: 1069-1069. DOI: 10.1158/1538-7445.Am2012-1069 |
0.37 |
|
| 2011 |
Blandino G, Deppert W, Hainaut P, Levine A, Lozano G, Olivier M, Rotter V, Wiman K, Oren M. Mutant p53 protein, master regulator of human malignancies: a report on the Fifth Mutant p53 Workshop. Cell Death and Differentiation. 19: 180-3. PMID 22095277 DOI: 10.1038/Cdd.2011.148 |
0.538 |
|
| 2011 |
Lin S, Yu L, Yang J, Liu Z, Karia B, Bishop AJ, Jackson J, Lozano G, Copland JA, Mu X, Sun B, Sun LZ. Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and -independent signaling activity of transforming growth factor-β (TGF-β). The Journal of Biological Chemistry. 286: 44023-34. PMID 22039050 DOI: 10.1074/Jbc.M111.265397 |
0.36 |
|
| 2011 |
Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK, Van Pelt C, Terzian T, Lozano G. Multiple stress signals activate mutant p53 in vivo. Cancer Research. 71: 7168-75. PMID 21983037 DOI: 10.1158/0008-5472.Can-11-0459 |
0.608 |
|
| 2011 |
Abbas HA, Pant V, Lozano G. The ups and downs of p53 regulation in hematopoietic stem cells. Cell Cycle (Georgetown, Tex.). 10: 3257-62. PMID 21957490 DOI: 10.4161/Cc.10.19.17721 |
0.555 |
|
| 2011 |
McEvoy J, Flores-Otero J, Zhang J, Nemeth K, Brennan R, Bradley C, Krafcik F, Rodriguez-Galindo C, Wilson M, Xiong S, Lozano G, Sage J, Fu L, Louhibi L, Trimarchi J, et al. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell. 20: 260-75. PMID 21840489 DOI: 10.1016/J.Ccr.2011.07.005 |
0.349 |
|
| 2011 |
Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, Mano M, Rosato A, Crook T, Scanziani E, Means AR, ... Lozano G, et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell. 20: 79-91. PMID 21741598 DOI: 10.1016/J.Ccr.2011.06.004 |
0.557 |
|
| 2011 |
Pant V, Xiong S, Iwakuma T, Quintás-Cardama A, Lozano G. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proceedings of the National Academy of Sciences of the United States of America. 108: 11995-2000. PMID 21730132 DOI: 10.1073/Pnas.1102241108 |
0.563 |
|
| 2011 |
Terzian T, Dumble M, Arbab F, Thaller C, Donehower LA, Lozano G, Justice MJ, Roop DR, Box NF. Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models. The Journal of Pathology. 224: 540-52. PMID 21674502 DOI: 10.1002/Path.2891 |
0.608 |
|
| 2011 |
Zhao R, Yeung SC, Chen J, Iwakuma T, Su CH, Chen B, Qu C, Zhang F, Chen YT, Lin YL, Lee DF, Jin F, Zhu R, Shaikenov T, Sarbassov D, ... ... Lozano G, et al. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. The Journal of Clinical Investigation. 121: 851-65. PMID 21317535 DOI: 10.1172/Jci44111 |
0.617 |
|
| 2011 |
Wu CC, Krahe R, Lozano G, Zhang B, Wilson CD, Jo EJ, Amos CI, Shete S, Strong LC. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome. Human Genetics. 129: 663-73. PMID 21305319 DOI: 10.1007/S00439-011-0957-1 |
0.329 |
|
| 2011 |
Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, Terzian T, Quintás-Cardama A, Bankson JA, El-Naggar AK, Lozano G. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. The Journal of Clinical Investigation. 121: 893-904. PMID 21285512 DOI: 10.1172/Jci44504 |
0.818 |
|
| 2011 |
Jackson JG, Post SM, Lozano G. Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. The Journal of Pathology. 223: 127-36. PMID 20957626 DOI: 10.1002/Path.2783 |
0.473 |
|
| 2011 |
Lin PP, Wang Y, Lozano G. Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma. Sarcoma. 2011. PMID 20953407 DOI: 10.1155/2011/276463 |
0.631 |
|
| 2011 |
Lozano G(. p53-Mediated Stress and Tissue-Dependent Cell Fate Decisions; Implications for p53 Targeting Blood. 118: SCI-3-SCI-3. DOI: 10.1182/blood.v118.21.sci-3.sci-3 |
0.536 |
|
| 2011 |
Xiong S, Suh Y, Quintás-Cardama A, Lozano G. Abstract 1459: Mining for metastasis genes in osteosarcomas fromp53+/R172Hmice Cancer Research. 71: 1459-1459. DOI: 10.1158/1538-7445.Am2011-1459 |
0.577 |
|
| 2011 |
Jackson JG, Chang LL, Quintás-Cardama A, El-Naggar AK, Lozano G. Abstract 1235: Induction of a p21 mediated senescence program by p53 impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer Cancer Research. 71: 1235-1235. DOI: 10.1158/1538-7445.Am2011-1235 |
0.616 |
|
| 2010 |
Abbas HA, Maccio DR, Coskun S, Jackson JG, Hazen AL, Sills TM, You MJ, Hirschi KK, Lozano G. Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell. 7: 606-17. PMID 21040902 DOI: 10.1016/J.Stem.2010.09.013 |
0.543 |
|
| 2010 |
Terzian T, Lozano G. Building p53. Genes & Development. 24: 2229-32. PMID 20952532 DOI: 10.1101/gad.1988510 |
0.443 |
|
| 2010 |
Addadi Y, Moskovits N, Granot D, Lozano G, Carmi Y, Apte RN, Neeman M, Oren M. p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner Cancer Research. 70: 9650-9658. PMID 20952507 DOI: 10.1158/0008-5472.Can-10-1146 |
0.591 |
|
| 2010 |
Terzian T, Torchia EC, Dai D, Robinson SE, Murao K, Stiegmann RA, Gonzalez V, Boyle GM, Powell MB, Pollock PM, Lozano G, Robinson WA, Roop DR, Box NF. p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell & Melanoma Research. 23: 781-94. PMID 20849464 DOI: 10.1111/J.1755-148X.2010.00773.X |
0.627 |
|
| 2010 |
Post SM, Quintás-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, Maccio DR, Bond GL, Johnson DG, Levine AJ, Lozano G. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell. 18: 220-30. PMID 20832750 DOI: 10.1016/J.Ccr.2010.07.010 |
0.59 |
|
| 2010 |
Post SM, Lozano G. You can win by losing: p53 mutations in rhabdomyosarcomas. The Journal of Pathology. 222: 124-8. PMID 20821751 DOI: 10.1002/Path.2757 |
0.593 |
|
| 2010 |
Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, Parker-Thornburg J, Shackleford TJ, Dai H, Lin SY, Lozano G, Rassidakis GZ, Claret FX. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene. 29: 6125-37. PMID 20802511 DOI: 10.1038/Onc.2010.345 |
0.416 |
|
| 2010 |
Xiong S, Pant V, Suh YA, Van Pelt CS, Wang Y, Valentin-Vega YA, Post SM, Lozano G. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Research. 70: 7148-54. PMID 20736370 DOI: 10.1158/0008-5472.Can-10-1457 |
0.856 |
|
| 2010 |
Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. Plos One. 5: e10813. PMID 20520810 DOI: 10.1371/Journal.Pone.0010813 |
0.45 |
|
| 2010 |
Nurieva RI, Zheng S, Jin W, Chung Y, Zhang Y, Martinez GJ, Reynolds JM, Wang SL, Lin X, Sun SC, Lozano G, Dong C. The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity. 32: 670-80. PMID 20493730 DOI: 10.1016/J.Immuni.2010.05.002 |
0.558 |
|
| 2010 |
Lozano G. Mouse models of p53 functions. Cold Spring Harbor Perspectives in Biology. 2: a001115. PMID 20452944 DOI: 10.1101/Cshperspect.A001115 |
0.648 |
|
| 2010 |
Odvody J, Vincent T, Arrate MP, Grieb B, Wang S, Garriga J, Lozano G, Iwakuma T, Haines DS, Eischen CM. A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis. Oncogene. 29: 3287-96. PMID 20305689 DOI: 10.1038/Onc.2010.82 |
0.516 |
|
| 2010 |
Post SM, Quintás-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G. p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Oncogene. 29: 1260-9. PMID 19935700 DOI: 10.1038/Onc.2009.423 |
0.595 |
|
| 2010 |
Marine JC, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death and Differentiation. 17: 93-102. PMID 19498444 DOI: 10.1038/Cdd.2009.68 |
0.543 |
|
| 2010 |
Suh Y, Post S, Elizondo C, El-Naggar AK, Xiong S, Lozano G. Abstract 1958: Signals activating mutant p53 in vivo Cancer Research. 70: 1958-1958. DOI: 10.1158/1538-7445.Am10-1958 |
0.652 |
|
| 2009 |
Donehower LA, Lozano G. 20 years studying p53 functions in genetically engineered mice. Nature Reviews. Cancer. 9: 831-41. PMID 19776746 DOI: 10.1038/Nrc2731 |
0.481 |
|
| 2009 |
Lin PP, Pandey MK, Jin F, Raymond AK, Akiyama H, Lozano G. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis. 30: 1789-95. PMID 19635748 DOI: 10.1093/Carcin/Bgp180 |
0.619 |
|
| 2009 |
Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, Yang Y, Raso MG, Liu DD, Wistuba II, Lozano G, Kurie JM. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. Plos One. 4: e5401. PMID 19404390 DOI: 10.1371/Journal.Pone.0005401 |
0.533 |
|
| 2009 |
Valentin-Vega YA, Box N, Terzian T, Lozano G. Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. Differentiation; Research in Biological Diversity. 77: 442-9. PMID 19371999 DOI: 10.1016/J.Diff.2009.03.001 |
0.86 |
|
| 2009 |
Eischen CM, Lozano G. p53 and MDM2: antagonists or partners in crime? Cancer Cell. 15: 161-2. PMID 19249672 DOI: 10.1016/J.Ccr.2009.02.004 |
0.43 |
|
| 2009 |
Lozano G. Abstract IA-3: The regulation of p53 tumor suppressing activities Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-Ia-3 |
0.602 |
|
| 2008 |
Molchadsky A, Shats I, Goldfinger N, Pevsner-Fischer M, Olson M, Rinon A, Tzahor E, Lozano G, Zipori D, Sarig R, Rotter V. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. Plos One. 3: e3707. PMID 19002260 DOI: 10.1371/Journal.Pone.0003707 |
0.454 |
|
| 2008 |
Lin PP, Pandey MK, Jin F, Xiong S, Deavers M, Parant JM, Lozano G. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Research. 68: 8968-75. PMID 18974141 DOI: 10.1158/0008-5472.Can-08-0573 |
0.537 |
|
| 2008 |
Valentin-Vega YA, Okano H, Lozano G. The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival. Cell Death and Differentiation. 15: 1772-81. PMID 18636077 DOI: 10.1038/Cdd.2008.109 |
0.841 |
|
| 2008 |
Barboza JA, Iwakuma T, Terzian T, El-Naggar AK, Lozano G. Mdm2 and Mdm4 loss regulates distinct p53 activities. Molecular Cancer Research : McR. 6: 947-54. PMID 18567799 DOI: 10.1158/1541-7786.Mcr-07-2079 |
0.865 |
|
| 2008 |
Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS, Lozano G. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes & Development. 22: 1337-44. PMID 18483220 DOI: 10.1101/Gad.1662908 |
0.838 |
|
| 2008 |
Atwal GS, Rabadán R, Lozano G, Strong LC, Ruijs MW, Schmidt MK, van't Veer LJ, Nevanlinna H, Tommiska J, Aittomäki K, Bougeard G, Frebourg T, Levine AJ, Bond GL. An information-theoretic analysis of genetics, gender and age in cancer patients. Plos One. 3: e1951. PMID 18398474 DOI: 10.1371/Journal.Pone.0001951 |
0.401 |
|
| 2008 |
Iwakuma T, Tochigi Y, Van Pelt CS, Caldwell LC, Terzian T, Parant JM, Chau GP, Koch JG, Eischen CM, Lozano G. Mtbp haploinsufficiency in mice increases tumor metastasis. Oncogene. 27: 1813-20. PMID 17906694 DOI: 10.1038/Sj.Onc.1210827 |
0.866 |
|
| 2008 |
Wergeland L, Spurgers KB, Oveland E, Høiby T, Cascallo M, Honda T, Lorens JB, Lozano G, McDonnell TJ, Gjertsen BT. Bcl-2 Protects against p53-Induced Apoptosis through Hdm2 Blood. 112: 5333-5333. DOI: 10.1182/Blood.V112.11.5333.5333 |
0.492 |
|
| 2007 |
Liu G, Terzian T, Xiong S, Van Pelt CS, Audiffred A, Box NF, Lozano G. The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. The Journal of Pathology. 213: 360-8. PMID 17893884 DOI: 10.1002/Path.2238 |
0.608 |
|
| 2007 |
Valentin-Vega YA, Barboza JA, Chau GP, El-Naggar AK, Lozano G. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Human Pathology. 38: 1553-62. PMID 17651783 DOI: 10.1016/J.Humpath.2007.03.005 |
0.822 |
|
| 2007 |
Caulin C, Nguyen T, Lang GA, Goepfert TM, Brinkley BR, Cai WW, Lozano G, Roop DR. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. The Journal of Clinical Investigation. 117: 1893-901. PMID 17607363 DOI: 10.1172/Jci31721 |
0.823 |
|
| 2007 |
Koch JG, Gu X, Han Y, El-Naggar AK, Olson MV, Medina D, Jerry DJ, Blackburn AC, Peltz G, Amos CI, Lozano G. Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mammalian Genome : Official Journal of the International Mammalian Genome Society. 18: 300-9. PMID 17557176 DOI: 10.1007/S00335-007-9028-2 |
0.833 |
|
| 2007 |
Xiong S, Van Pelt CS, Elizondo-Fraire AC, Fernandez-Garcia B, Lozano G. Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation. 115: 2925-30. PMID 17533180 DOI: 10.1161/Circulationaha.107.689901 |
0.558 |
|
| 2007 |
Terzian T, Wang Y, Van Pelt CS, Box NF, Travis EL, Lozano G. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Molecular and Cellular Biology. 27: 5479-85. PMID 17526734 DOI: 10.1128/Mcb.00555-06 |
0.816 |
|
| 2007 |
Zheng S, El-Naggar AK, Kim ES, Kurie JM, Lozano G. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene. 26: 6896-904. PMID 17486075 DOI: 10.1038/Sj.Onc.1210493 |
0.563 |
|
| 2007 |
Iwakuma T, Lozano G. Crippling p53 activities via knock-in mutations in mouse models. Oncogene. 26: 2177-84. PMID 17401426 DOI: 10.1038/Sj.Onc.1210278 |
0.647 |
|
| 2007 |
Cosme-Blanco W, Shen MF, Lazar AJ, Pathak S, Lozano G, Multani AS, Chang S. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. Embo Reports. 8: 497-503. PMID 17396137 DOI: 10.1038/Sj.Embor.7400937 |
0.589 |
|
| 2007 |
Lozano G, Behringer RR. New mouse models of cancer: single-cell knockouts. Proceedings of the National Academy of Sciences of the United States of America. 104: 4245-6. PMID 17360508 DOI: 10.1073/Pnas.0700173104 |
0.454 |
|
| 2007 |
Bu P, Evrard YA, Lozano G, Dent SY. Loss of Gcn5 acetyltransferase activity leads to neural tube closure defects and exencephaly in mouse embryos. Molecular and Cellular Biology. 27: 3405-16. PMID 17325035 DOI: 10.1128/Mcb.00066-07 |
0.452 |
|
| 2007 |
Lozano G. The oncogenic roles of p53 mutants in mouse models. Current Opinion in Genetics & Development. 17: 66-70. PMID 17208429 DOI: 10.1016/J.Gde.2006.12.003 |
0.664 |
|
| 2007 |
Han X, Garcia-Manero G, McDonnell TJ, Lozano G, Medeiros LJ, Xiao L, Rosner G, Nguyen M, Fernandez M, Valentin-Vega YA, Barboza J, Jones DM, Rassidakis GZ, Kantarjian HM, Bueso-Ramos CE. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 20: 54-62. PMID 17143258 DOI: 10.1038/Modpathol.3800727 |
0.787 |
|
| 2007 |
Maetens M, Doumont G, Clercq SD, Francoz S, Froment P, Bellefroid E, Klingmuller U, Lozano G, Marine JC. Distinct roles of Mdm2 and Mdm4 in red cell production. Blood. 109: 2630-3. PMID 17105817 DOI: 10.1182/Blood-2006-03-013656 |
0.56 |
|
| 2006 |
Barboza JA, Liu G, Ju Z, El-Naggar AK, Lozano G. p21 delays tumor onset by preservation of chromosomal stability. Proceedings of the National Academy of Sciences of the United States of America. 103: 19842-7. PMID 17170138 DOI: 10.1073/Pnas.0606343104 |
0.839 |
|
| 2006 |
Chandler DS, Singh RK, Caldwell LC, Bitler JL, Lozano G. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Research. 66: 9502-8. PMID 17018606 DOI: 10.1158/0008-5472.Can-05-4271 |
0.575 |
|
| 2006 |
Lee MH, Lozano G. Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. Seminars in Cancer Biology. 16: 225-34. PMID 16697215 DOI: 10.1016/J.Semcancer.2006.03.009 |
0.57 |
|
| 2006 |
Ayanga B, Price R, Gu X, Lozano G, Evans SC. Genetic mapping of a putative tumor suppressor locus that influences tumorigenesis and metastasis in mice. Genes, Chromosomes & Cancer. 45: 668-75. PMID 16586494 DOI: 10.1002/Gcc.20328 |
0.452 |
|
| 2006 |
Marine J, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death & Differentiation. 13: 927-934. PMID 16543935 DOI: 10.1038/Sj.Cdd.4401912 |
0.311 |
|
| 2006 |
Xiong S, Van Pelt CS, Elizondo-Fraire AC, Liu G, Lozano G. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proceedings of the National Academy of Sciences of the United States of America. 103: 3226-31. PMID 16492743 DOI: 10.1073/Pnas.0508500103 |
0.591 |
|
| 2006 |
Grier JD, Xiong S, Elizondo-Fraire AC, Parant JM, Lozano G. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Molecular and Cellular Biology. 26: 192-8. PMID 16354690 DOI: 10.1128/Mcb.26.1.192-198.2006 |
0.851 |
|
| 2005 |
Lozano G, Zambetti GP. Gankyrin: an intriguing name for a novel regulator of p53 and RB. Cancer Cell. 8: 3-4. PMID 16023592 DOI: 10.1016/J.Ccr.2005.06.014 |
0.526 |
|
| 2005 |
Slack A, Lozano G, Shohet JM. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. Cancer Letters. 228: 21-7. PMID 15927364 DOI: 10.1016/J.Canlet.2005.01.050 |
0.542 |
|
| 2005 |
Iwakuma T, Lozano G, Flores ER. Li-Fraumeni syndrome: a p53 family affair. Cell Cycle (Georgetown, Tex.). 4: 865-7. PMID 15917654 DOI: 10.4161/Cc.4.7.1800 |
0.605 |
|
| 2005 |
Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochemical and Biophysical Research Communications. 331: 834-42. PMID 15865939 DOI: 10.1016/J.Bbrc.2005.03.190 |
0.607 |
|
| 2005 |
Huang W, Zhang J, Washington M, Liu J, Parant JM, Lozano G, Moore DD. Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Molecular Endocrinology (Baltimore, Md.). 19: 1646-53. PMID 15831521 DOI: 10.1210/Me.2004-0520 |
0.332 |
|
| 2005 |
Liu G, Lozano G. p21 stability: linking chaperones to a cell cycle checkpoint. Cancer Cell. 7: 113-4. PMID 15710322 DOI: 10.1016/J.Ccr.2005.01.019 |
0.493 |
|
| 2005 |
Bachinski LL, Olufemi SE, Zhou X, Wu CC, Yip L, Shete S, Lozano G, Amos CI, Strong LC, Krahe R. Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23. Cancer Research. 65: 427-31. PMID 15695383 |
0.326 |
|
| 2005 |
Lozano G, Zambetti GP. What have animal models taught us about the p53 pathway? The Journal of Pathology. 205: 206-20. PMID 15643668 DOI: 10.1002/Path.1704 |
0.616 |
|
| 2004 |
Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 119: 861-72. PMID 15607981 DOI: 10.1016/J.Cell.2004.11.006 |
0.847 |
|
| 2004 |
Li Z, Day CP, Yang JY, Tsai WB, Lozano G, Shih HM, Hung MC. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Cancer Research. 64: 9080-5. PMID 15604276 DOI: 10.1158/0008-5472.Can-04-2419 |
0.585 |
|
| 2004 |
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 119: 591-602. PMID 15550242 DOI: 10.1016/J.Cell.2004.11.022 |
0.535 |
|
| 2004 |
Bruins W, Zwart E, Attardi LD, Iwakuma T, Hoogervorst EM, Beems RB, Miranda B, Van Oostrom CTM, Van Den Berg J, Van Den Aardweg GJ, Lozano G, Van Steeg H, Jacks T, De Vries A. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389 Molecular and Cellular Biology. 24: 8884-8894. PMID 15456863 DOI: 10.1128/Mcb.24.20.8884-8894.2004 |
0.604 |
|
| 2004 |
Iwakuma T, Parant JM, Fasulo M, Zwart E, Jacks T, de Vries A, Lozano G. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene. 23: 7644-50. PMID 15361844 DOI: 10.1038/Sj.Onc.1207793 |
0.642 |
|
| 2004 |
Evans SC, Liang M, Amos C, Gu X, Lozano G. A novel genetic modifier of p53, mop1, results in embryonic lethality. Mammalian Genome : Official Journal of the International Mammalian Genome Society. 15: 415-23. PMID 15181534 DOI: 10.1007/S00335-004-2327-Y |
0.579 |
|
| 2004 |
Obeyesekere MN, Tecarro E, Lozano G. Model predictions of MDM2 mediated cell regulation. Cell Cycle (Georgetown, Tex.). 3: 655-61. PMID 15107623 DOI: 10.4161/Cc.3.5.854 |
0.31 |
|
| 2004 |
Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK, Multani A, Chang S, Lozano G. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nature Genetics. 36: 63-8. PMID 14702042 DOI: 10.1038/Ng1282 |
0.816 |
|
| 2004 |
Horn EJ, Albor A, Liu Y, El-Hizawi S, Vanderbeek GE, Babcock M, Bowden GT, Hennings H, Lozano G, Weinberg WC, Kulesz-Martin M. RING protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties Carcinogenesis. 25: 157-167. PMID 14578165 DOI: 10.1093/Carcin/Bgh003 |
0.428 |
|
| 2003 |
Iwakuma T, Lozano G. MDM2, an introduction. Molecular Cancer Research : McR. 1: 993-1000. PMID 14707282 |
0.561 |
|
| 2003 |
Chavez-Reyes A, Parant JM, Amelse LL, de Oca Luna RM, Korsmeyer SJ, Lozano G. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Research. 63: 8664-9. PMID 14695178 |
0.537 |
|
| 2003 |
Wong SS, Lozano G, Gaff CL, Gardner RJ, Strong LC, Aittomäki K, Lindeman GJ. Novel p53 germline mutation in a patient with Li-Fraumeni syndrome. Internal Medicine Journal. 33: 621. PMID 14656244 DOI: 10.1111/J.1445-5994.2003.00487.X |
0.416 |
|
| 2003 |
Yang HY, Wen YY, Chen CH, Lozano G, Lee MH. 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Molecular and Cellular Biology. 23: 7096-107. PMID 14517281 DOI: 10.1128/Mcb.23.20.7096-7107.2003 |
0.617 |
|
| 2003 |
Hwang SJ, Cheng LS, Lozano G, Amos CI, Gu X, Strong LC. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Human Genetics. 113: 238-43. PMID 12802680 DOI: 10.1007/S00439-003-0968-7 |
0.312 |
|
| 2003 |
Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R, Benchimol S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 112: 779-91. PMID 12654245 DOI: 10.1016/S0092-8674(03)00193-4 |
0.604 |
|
| 2003 |
Parant JM, Lozano G. Disrupting TP53 in mouse models of human cancers. Human Mutation. 21: 321-6. PMID 12619119 DOI: 10.1002/Humu.10186 |
0.6 |
|
| 2003 |
Hwang SJ, Lozano G, Amos CI, Strong LC. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. American Journal of Human Genetics. 72: 975-83. PMID 12610779 DOI: 10.1086/374567 |
0.453 |
|
| 2003 |
Lu X, Lozano G, Donehower LA. Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system. Mutation Research. 522: 69-83. PMID 12517413 DOI: 10.1016/S0027-5107(02)00261-0 |
0.504 |
|
| 2002 |
Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchénio T, Lozano G, Harel-Bellan A. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proceedings of the National Academy of Sciences of the United States of America. 99: 14849-54. PMID 12403821 DOI: 10.1073/Pnas.222406899 |
0.489 |
|
| 2002 |
Jabbur JR, Tabor AD, Cheng X, Wang H, Uesugi M, Lozano G, Zhang W. Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene. 21: 7100-13. PMID 12370832 DOI: 10.1038/Sj.Onc.1205856 |
0.528 |
|
| 2002 |
Foster CJ, Lozano G. Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland. Oncogene. 21: 3525-31. PMID 12032854 DOI: 10.1038/Sj.Onc.1205441 |
0.523 |
|
| 2002 |
Santamaria AB, Davis DW, Nghiem DX, McConkey DJ, Ullrich SE, Kapoor M, Lozano G, Ananthaswamy HN. p53 and Fas ligand are required for psoralen and UVA-induced apoptosis in mouse epidermal cells. Cell Death and Differentiation. 9: 549-60. PMID 11973613 DOI: 10.1038/Sj.Cdd.4401007 |
0.505 |
|
| 2002 |
Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG, Parant J, Lozano G, Yuan ZM. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. The Journal of Biological Chemistry. 277: 19251-4. PMID 11953423 DOI: 10.1074/Jbc.C200150200 |
0.639 |
|
| 2002 |
Grier JD, Yan W, Lozano G. Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis (New York, N.Y. : 2000). 32: 145-7. PMID 11857803 DOI: 10.1002/Gene.10066 |
0.82 |
|
| 2001 |
Schmidt M, Lu Y, Parant JM, Lozano G, Bacher G, Beckers T, Fan Z. Differential roles of p21(Waf1) and p27(Kip1) in modulating chemosensitivity and their possible application in drug discovery studies. Molecular Pharmacology. 60: 900-6. PMID 11641417 DOI: 10.1124/Mol.60.5.900 |
0.544 |
|
| 2001 |
Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nature Genetics. 29: 92-5. PMID 11528400 DOI: 10.1038/Ng714 |
0.628 |
|
| 2001 |
Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene. 20: 4041-9. PMID 11494132 DOI: 10.1038/Sj.Onc.1204533 |
0.85 |
|
| 2001 |
Parant JM, Reinke V, Mims B, Lozano G. Organization, expression, and localization of the murine mdmx gene and pseudogene. Gene. 270: 277-83. PMID 11404026 DOI: 10.1016/S0378-1119(01)00432-2 |
0.409 |
|
| 2001 |
El-Naggar AK, Lai S, Clayman GL, Mims B, Lippman SM, Coombes M, Luna MA, Lozano G. p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. Carcinogenesis. 22: 729-35. PMID 11323391 DOI: 10.1093/Carcin/22.5.729 |
0.575 |
|
| 2001 |
Keller DM, Zeng X, Wang Y, Zhang QH, Kapoor M, Shu H, Goodman R, Lozano G, Zhao Y, Lu H. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Molecular Cell. 7: 283-92. PMID 11239457 DOI: 10.1016/S1097-2765(01)00176-9 |
0.687 |
|
| 2000 |
Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP. p53-independent functions of the p19(ARF) tumor suppressor. Genes & Development. 14: 2358-65. PMID 10995391 DOI: 10.1101/Gad.827300 |
0.658 |
|
| 2000 |
de Rozieres S, Maya R, Oren M, Lozano G. The loss of mdm2 induces p53-mediated apoptosis. Oncogene. 19: 1691-7. PMID 10763826 DOI: 10.1038/Sj.Onc.1203468 |
0.632 |
|
| 2000 |
Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK, Lozano G. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proceedings of the National Academy of Sciences of the United States of America. 97: 4174-9. PMID 10760284 DOI: 10.1073/Pnas.97.8.4174 |
0.609 |
|
| 2000 |
Lozano G, Elledge SJ. p53 Sends nucleotides to repair DNA Nature. 404: 24-25. PMID 10716425 DOI: 10.1038/35003670 |
0.508 |
|
| 2000 |
Kapoor M, Hamm R, Yan W, Taya Y, Lozano G. Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene. 19: 358-64. PMID 10656682 DOI: 10.1038/Sj.Onc.1203300 |
0.485 |
|
| 2000 |
McDonnell TJ, Montes de Oca Luna R, Cho S, Amelse LL, Chavez-Reyes A, Lozano G. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. The Journal of Pathology. 188: 322-8. PMID 10419603 DOI: 10.1002/(Sici)1096-9896(199907)188:3<322::Aid-Path372>3.0.Co;2-F |
0.602 |
|
| 1999 |
Casau AE, Vaughan JE, Lozano G, Levine AJ. Germ cell expression of an isolated human endogenous retroviral long terminal repeat of the HERV-K/HTDV family in transgenic mice. Journal of Virology. 73: 9976-83. PMID 10559311 DOI: 10.1128/Jvi.73.12.9976-9983.1999 |
0.418 |
|
| 1999 |
Hung JY, Mims B, Lozano G, Strong L, Harvey C, Chen TTY, Stastny V, Tomlinson G. TP53 mutation and haplotype analysis of two large African American families. Human Mutation. 14: 216-221. PMID 10477429 DOI: 10.1002/(Sici)1098-1004(1999)14:3<216::Aid-Humu4>3.0.Co;2-X |
0.303 |
|
| 1999 |
Keller D, Zeng X, Li X, Kapoor M, Iordanov MS, Taya Y, Lozano G, Magun B, Lu H. The p38MAPK inhibitor SB203580 alleviates ultraviolet-induced phosphorylation at serine 389 but not serine 15 and activation of p53. Biochemical and Biophysical Research Communications. 261: 464-71. PMID 10425208 DOI: 10.1006/Bbrc.1999.1023 |
0.497 |
|
| 1999 |
Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G, Oren M, Haupt Y. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. The Embo Journal. 18: 1805-14. PMID 10202144 DOI: 10.1093/Emboj/18.7.1805 |
0.584 |
|
| 1999 |
Evans SC, Foster CJ, El-Naggar AK, Lozano G. Mapping and mutational analysis of the human TAF2G gene encoding a p53 cofactor Genomics. 57: 182-183. PMID 10191103 DOI: 10.1006/Geno.1999.5745 |
0.421 |
|
| 1999 |
Lozano G, Liu G. Mouse models dissect the role of p53 in cancer and development. Seminars in Cancer Biology. 8: 337-44. PMID 10101799 DOI: 10.1006/scbi.1998.0096 |
0.526 |
|
| 1999 |
Kapoor M, Montes de Oca Luna R, Liu G, Lozano G, Cummings C, Mancini M, Ouspenski I, Brinkley BR, May GS. The cenpB gene is not essential in mice. Chromosoma. 107: 570-6. PMID 9933410 DOI: 10.1007/S004120050343 |
0.33 |
|
| 1998 |
Evans SC, Minis B, McMasters KM, Foster CJ, DeAndrade M, Amos CI, Strong LC, Lozano G. Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family Human Genetics. 102: 681-686. PMID 9703430 DOI: 10.1007/S004390050761 |
0.504 |
|
| 1998 |
Zou Y, Zong G, Ling YH, Hao MM, Lozano G, Hong WK, Perez-Soler R. Effective Treatment of Early Endobronchial Cancer With Regional Administration of Liposome-p53 Complexes Journal of the National Cancer Institute. 90: 1130-1137. PMID 9701362 DOI: 10.1093/Jnci/90.15.1130 |
0.593 |
|
| 1998 |
Anaya P, Evans SC, Dai C, Lozano G, May GS. Isolation of the Aspergillus nidulans sudD gene and its human homologue Gene. 211: 323-329. PMID 9602165 DOI: 10.1016/S0378-1119(98)00115-2 |
0.308 |
|
| 1998 |
Kapoor M, Lozano G. Functional activation of p53 via phosphorylation following DNA damage by UV but not γ radiation Proceedings of the National Academy of Sciences of the United States of America. 95: 2834-2837. PMID 9501176 DOI: 10.1073/Pnas.95.6.2834 |
0.437 |
|
| 1997 |
Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, Lopez-Berestein G, Lozano G, Sarkiss M, McDonnell TJ. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene. 15: 2767-72. PMID 9419967 DOI: 10.1038/Sj.Onc.1201464 |
0.379 |
|
| 1997 |
Reinke V, Lozano G. The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene. 15: 1527-34. PMID 9380404 DOI: 10.1038/Sj.Onc.1201316 |
0.569 |
|
| 1997 |
Evans SC, Lozano G. The Li-Fraumeni syndrome: An inherited susceptibility to cancer Molecular Medicine Today. 3: 390-395. PMID 9302689 DOI: 10.1016/S1357-4310(97)01105-2 |
0.435 |
|
| 1997 |
Montes de Oca Luna R, Amelse LL, Chavez-Reyes A, Evans SC, Brugarolas J, Jacks T, Lozano G. Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nature Genetics. 16: 336-7. PMID 9241268 DOI: 10.1038/Ng0897-336 |
0.587 |
|
| 1997 |
Lundgren K, Montes de Oca Luna R, McNeill YB, Emerick EP, Spencer B, Barfield CR, Lozano G, Rosenberg MP, Finlay CA. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes & Development. 11: 714-25. PMID 9087426 DOI: 10.1101/Gad.11.6.714 |
0.636 |
|
| 1997 |
Hao M, Lowy AM, Kapoor M, Deffie A, Liu G, Lozano G. Mutation of phosphoserine 389 affects p53 function in vivo. The Journal of Biological Chemistry. 271: 29380-5. PMID 8910602 DOI: 10.1074/Jbc.271.46.29380 |
0.521 |
|
| 1997 |
Reinke V, Lozano G. Differential Activation of p53 Targets in Cells Treated with Ultraviolet Radiation That Undergo Both Apoptosis and Growth Arrest Radiation Research. 148: 115. DOI: 10.2307/3579567 |
0.494 |
|
| 1996 |
Luna RMdO, Tabor AD, Eberspaecher H, Hulboy DL, Worth LL, Colman MS, Finlay CA, Lozano G. The organization and expression of the mdm2 gene Genomics. 33: 352-357. PMID 8660994 DOI: 10.1006/Geno.1996.0210 |
0.424 |
|
| 1995 |
Deffie A, Hao M, Montes de Oca Luna R, Hulboy DL, Lozano G. Cyclin E restores p53 activity in contact-inhibited cells. Molecular and Cellular Biology. 15: 3926-33. PMID 7791798 DOI: 10.1128/Mcb.15.7.3926 |
0.502 |
|
| 1995 |
Ghebranious N, Knoll BJ, Wu H, Lozano G, Sell S. Characterization of a murine p53ser246 mutant equivalent to the human p53ser249 associated with hepatocellular carcinoma and aflatoxin exposure. Molecular Carcinogenesis. 13: 104-11. PMID 7605578 DOI: 10.1002/Mc.2940130207 |
0.508 |
|
| 1995 |
de Vente JE, Kukoly CA, Bryant WO, Posekany KJ, Chen J, Fletcher DJ, Parker PJ, Pettit GJ, Lozano G, Cook PP. Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death. The Journal of Clinical Investigation. 96: 1874-86. PMID 7560079 DOI: 10.1172/Jci118233 |
0.391 |
|
| 1995 |
Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 378: 203-6. PMID 7477326 DOI: 10.1038/378203A0 |
0.628 |
|
| 1994 |
Mu ZM, Chin KV, Liu JH, Lozano G, Chang KS. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Molecular and Cellular Biology. 14: 6858-67. PMID 7935403 DOI: 10.1128/Mcb.14.10.6858 |
0.302 |
|
| 1993 |
Deffie A, Wu H, Reinke V, Lozano G. The tumor suppressor p53 regulates its own transcription. Molecular and Cellular Biology. 13: 3415-23. PMID 7684498 DOI: 10.1128/Mcb.13.6.3415 |
0.579 |
|
| 1992 |
Beenken SW, Raycroft L, Lozano G. Inhibition of the mutant p53 gene in transformation assays. Journal of Surgical Research. 52: 401-405. PMID 1593878 DOI: 10.1016/0022-4804(92)90123-H |
0.486 |
|
| 1991 |
Garofalo S, Vuorio E, Metsaranta M, Rosati R, Toman D, Vaughan J, Lozano G, Mayne R, Ellard J, Horton W. Reduced amounts of cartilage collagen fibrils and growth plate anomalies in transgenic mice harboring a glycine-to-cysteine mutation in the mouse type II procollagen alpha 1-chain gene. Proceedings of the National Academy of Sciences of the United States of America. 88: 9648-52. PMID 1946380 DOI: 10.1073/Pnas.88.21.9648 |
0.324 |
|
| 1991 |
Raycroft L, Schmidt JR, Yoas K, Hao MM, Lozano G. Analysis of p53 mutants for transcriptional activity. Molecular and Cellular Biology. 11: 6067-74. PMID 1944276 DOI: 10.1128/Mcb.11.12.6067 |
0.56 |
|
| 1991 |
Beenken SW, Karsenty G, Raycroft L, Lozano G. An intron binding protein is required for transformation ability of p53. Nucleic Acids Research. 19: 4747-52. PMID 1891364 DOI: 10.1093/Nar/19.17.4747 |
0.473 |
|
| 1991 |
Lozano G, Levine AJ. Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Molecular Carcinogenesis. 4: 3-9. PMID 1848986 DOI: 10.1002/Mc.2940040103 |
0.504 |
|
| 1990 |
Raycroft L, Wu HY, Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science (New York, N.Y.). 249: 1049-51. PMID 2144364 DOI: 10.1126/Science.2144364 |
0.532 |
|
| 1987 |
van Dyke TA, Finlay C, Miller D, Marks J, Lozano G, Levine AJ. Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice Journal of Virology. 61: 2029-2032. PMID 3033329 DOI: 10.1128/Jvi.61.6.2029-2032.1987 |
0.4 |
|
| 1987 |
Yagaloff KA, Lozano G, van Dyke T, Levine AJ, Hartig PR. Serotonin 5-HT1C receptors are expressed at high density on choroid plexus tumors from transgenic mice. Brain Research. 385: 389-94. PMID 3022874 DOI: 10.1016/0006-8993(86)91089-9 |
0.407 |
|
| Show low-probability matches. |